260 results about "Chemokine" patented technology

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate-to-severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, comprising selecting a subject having AD and an elevated level of at least one biomarker selected from the group consisting of thymus and activation-regulated chemokine (TARC), interleukin-5 (IL-5), eosinophil count, and lactate dehydrogenase (LDH) relative to a control.

The invention relates to application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer, and belongs to the technical field of biological medicine. The invention discloses application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer. The GATA3 regulates the transcription regulation of IFNbeta by inhibiting the enhancer activity of IFNB1, down-regulates an I-type interferon signal channel, inhibits the secretion of an MHC-I antigen presentation channel and a chemotactic factor CCL5 of breast cancer cells, reduces immune recognition, and achieves the purpose of immune escape. The immunotherapy for inhibiting GATA3 combined with the PD1 inhibitor to treat breast cancer effectively treats breast cancer mice, improves the IFN beta level in the mice, promotes the MHC-I antigen presentation pathway of the mice, improves the CCL5 level in the mice, and improves the CD8 + T cell level in a tumor immune microenvironment, thereby reducing tumor occurrence and inhibiting tumor growth.

Provided herein, inter alia, are oncolytic viruses that express recombinant proteins having bispecific activity. The recombinant proteins include a first fusion protein comprising a first Fc domain covalently linked to a chemokine domain, and a second Fc fusion protein comprising a second Fc domain covalently linked to an anticancer therapeutic antibody domain. The recombinant proteins and oncolytic viruses provided herein are contemplated to be effective for the treatment of cancer, particularly by trafficking immune cells to the tumor microenvironment.

The invention relates to application of a cGAS-STING signal channel inhibitor in preparation of a product for preventing or treating abdominal adhesion, and belongs to the technical field of biological medicines. The invention finds that peritoneal dialysis causes that a peritoneal mesothelial cell cGAS-STING pathway and downstream protein thereof are activated, inflammatory factors are generated, and the peritoneal mesothelial cell secretes a chemotactic factor CCL2 (MCP-1) participating in macrophage recruitment, so that migration of macrophages can be promoted, and abdominal adhesion is caused. The cGAS-STING signaling pathway inhibitor can be used for relieving the effects, so that the aim of treating abdominal adhesion is fulfilled.

The invention discloses a chemokine receptor antagonist, a pharmaceutical composition and application. Specifically, the invention discloses a compound as shown in a formula I, a formula II or a formula III or pharmaceutically acceptable salt thereof, or a deuterated substance thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a prodrug or a metabolite thereof. The compound provided by the invention has better inhibitory activity on CCR4, and can be used for treating or preventing diseases mediated by CCR4. # imgabs0 #

Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.

The present disclosure provides a method of identifying a tumor for immunotherapy. The method comprises culturing tumor cells obtained from a subject; exposing the tumor cells to nanoparticles comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer; and measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells. A method of treating a subject with cancer also is provided. The method comprises culturing tumor cells from the subject; exposing the tumor cells to the nanoparticles; measuring interferon-alpha and interleukin 6 (and optionally Chemokine (C-C motif) ligands 4) produced by the tumor cells; and administering an immune checkpoint inhibitor to the subject. Any of the methods may also comprise measuring CXCL 10.

Antibodies and antibody fragments that bind to BDCA2 are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to induce death of a plasmacytoid dendritic cell, inhibit production or secretion of inflammatory cytokines and chemokines, and treat or prevent immunological disorders such as inflammatory and autoimmune conditions.

The present invention discloses the use of 3,4-dihydropsoralen in the preparation of a drug for preventing or treating rheumatoid arthritis. The present invention simulates RA by constructing TNF-a-induced SW982 cells. The results show that 3,4-dihydropsoralen (DP) can downregulate the mRNA expression of inflammatory factors, chemokines, and matrix degrading enzymes through the IL-17 signaling pathway, and affect the IL-17 signaling pathway and the NF-κB signaling pathway to jointly exert an anti-inflammatory effect, thereby effectively improving rheumatoid arthritis. This provides a theoretical basis for the application of 3,4-dihydropsoralen in the clinical treatment of rheumatoid arthritis and opens up new therapeutic drugs and approaches.

A method for characterizing disease activity in a systemic lupus erythematosus patient (SLE), comprising obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, assessing the dataset for a presence or an amount of protein expression of at least one innate serum or plasma mediator, assessing the dataset for a presence or an amount of protein expression of at least one adaptive serum or plasma mediator biomarker, assessing the dataset for a presence or an amount of at least one chemokine / adhesion molecule biomarker, assessing the dataset for a presence or an amount of at least one soluble TNF superfamily biomarker, assessing the dataset for a presence or an amount of at least one inflammatory mediator biomarker, assessing the dataset for a presence or an amount at least one SLE-associated autoantibody specificity biomarker and calculating a Lupus Disease Activity Immune Index (LDAII) score.

The present application relates to a pharmaceutical composition for wound treatment. Specifically, the present application concerns a composition including a wound-coating material and chemokine-adsorbing particles to absorb inflammatory chemokines that cause excessive immune responses, thereby allowing active wound healing.

Disclosed herein are methods of gene editing, or endogenous suppression, of cytokines / chemokines / transcription factors secreted from chimeric antigen receptor (CAR)-bearing immune effector cell such as CAR-T cells for the mitigation of cytokine release syndrome and / or CAR-T associated neuropathy. These methods involve insertion of the CAR into a locus of a cytokine gene, blocking its expression. Also disclosed herein are (CAR)-bearing immune effector cells with CARs inserted into a locus of a cytokine gene, and methods of treatment of diseases with immunotherapy with a reduced incidence of cytokine release syndrome and / or CAR-T associated neuropathy.

Methods of assigning a COVID pathological type for a subject suffering from COVID-19 are provided. Aspects of the methods include assigning a COVID pathological type for the subject based on a determined quantitative, multiplex cytokine / chemokine panel in a test sample from the subject. Also provided are methods of treating a subject (e.g., a long hauler subject) for chronic COVID-19. Aspects of such methods include administering to the long hauler subject a CCR5 / CCL5 interaction inhibitor to treat the long hauler subject. Also provided are compositions for use in practicing the methods. The methods and compositions find use in a variety of applications, including patient stratification, treatment and therapy determination and therapy response assessment.

A method to obtain more effective CAR-T cells, which are FOXO1 inhibited. The inhibition of FOXO1 potentiates the ability to induce lysis of a target cell thanks to the increased expression of TNF-α and other inflammatory cytokines, induces spontaneous cell polarization comparable to that obtained by stimulation with chemokines and thus improves the motility of the cells, induces a sharp increase of memory T cells and allows to obtain more efficient CAR-T cells to treat solid tumors than classical CAR-T cells obtained with the known protocol. An 10 ex vivo method to obtain improved CAR-T cells including the steps of (i) cultivate T cells obtained from a subject with a FOXO1 inhibitor during a time of 2 to 10 days; (ii) transducing (or transforming) the T cells into CAR-T cells thanks to a known method.

Methods of identifying and assays designed to identify at least one biomolecule from a patient are disclosed that comprise: collecting at least one biofluid from a patient, isolating at least one exosome from the biofluid, and identifying at least one biomolecule from the at least one exosome, wherein the at least one biomolecule is bound to the at least one exosome and is locally released from the patient. In some embodiments, the at least one biomolecule comprises a secretory protein, a neurotrophic factor, a growth factor, a cytokine, a chemokine, a pre-toxic molecule, a toxic molecule, or a combination thereof.

The invention discloses a chimeric antigen receptor double-negative T cell drug co-expressing CXCR5 and IL-7 and application thereof, the cell drug can co-express CXCR5 and IL-7, and the cell drug comprises EF1-alpha, a CD8 alpha signal peptide, an NKG2D extracellular domain, a CD8 alpha hinge region, a CD8 alpha transmembrane region, a costimulatory factor 4-1BB, a CD3 zeta intracellular signal region, T2A, a chemotactic factor receptor CXCR5, P2A and interleukin IL-7 which are connected in sequence; according to the chimeric antigen receptor double-negative T cell drug co-expressing the CXCR5 and the IL-7 and the application of the chimeric antigen receptor double-negative T cell drug, the CXCR5 and the IL-7 are co-expressed on CAR-DNT cells of targeted NKG2DL, so that the migration and infiltration capacity of the drug to a tumor site is enhanced, the survival and proliferation capacity of the CAR-T cells is improved, the killing effect of the CAR-DNT cells on tumors is improved, and the drug has a good application prospect. The purpose of treating tumors is achieved, and allogenic treatment can be achieved.

The present invention relates to a C-X-C motif chemokine 12 (CXCL12) antagonist for use in a method of treating a brain tumor in a subject wherein the method comprises administering to the subject a C-X-C motif chemokine 12 (CXCL12) antagonist, a radiation therapy, and an angiogenic compound wherein the tumor is a brain tumor.

The invention provides hydrogel, a porous titanium / hydrogel composite implant material and a preparation method of the porous titanium / hydrogel composite implant material. The hydrogel is obtained by photo-crosslinking and curing a hydrogel precursor solution containing acrylated beta-cyclodextrin, acrylated alendronate sodium, gelatin and a chemotactic factor. The hydrogel has a porous network structure, high elastic modulus, high fatigue resistance and excellent biocompatibility, and also has the capability of recruiting bone marrow mesenchymal stem cells (BMSCs) and the capability of promoting osteogenic differentiation of the BMSCs; the porous titanium / hydrogel composite implant material prepared from the hydrogel can effectively promote the growth of new bone tissues, has excellent osseointegration capability, obviously improves the osteogenesis repair effect and the osseointegration effect, provides a new treatment approach for the repair treatment of segmental bone defects, and has important medical significance.

Embodiments of the disclosure include methods and compositions for the treatment of splenomegaly. In specific embodiments, fibroblasts and / or fibroblast-derived materials, are utilized in at least some cases to affect the immune response of the individual in order to reduce the pathogenic levels of immune cells or cytokines and / or chemokines excreted by those immune cells.

The present disclosure relates to anti-CCR8 (chemokine (C-C motif) receptor 8) antibodies, antigen binding fragments and uses thereof.

The present invention is related to a C—X—C motif chemokine 12 (CXCL12) antagonist for use in a method for treating a tumor in a subject, wherein the method comprises administering to the subject—the C—X—C motif chemokine 12 (CXCL12) antagonist, —a radiotherapy, and—an anti-angiogenic compound, wherein the tumor is a brain tumor.

The invention relates to the field of stem cell biology, and discloses a culture solution and a method for differentiating human pluripotent stem cells into natural killer cells. The culture solution comprises a DMEM (Dulbecco Modified Eagle Medium), an F12 culture medium, an APEL blood cell culture medium, an induction factor, a chemotactic factor CXCL12, L-ascorbic acid, L-glutamine, beta-mercaptoethanol, sodium selenite, ethanolamine and penicillin-streptomycin. The invention also discloses a more efficient differentiation method for inducing the human induced pluripotent stem cells to differentiate into the NK cells, and the differentiation method provided by the invention can rapidly, efficiently, simply and conveniently induce the pluripotent stem cells to differentiate into the natural killer cells at low cost based on a culture medium with definite components and an optimized cell factor combination.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate to severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, the method comprises selecting a subject suffering from AD and having an elevated level relative to a control of at least one biomarker selected from the group consisting of thymus activation regulatory chemokine (TARC), interleukin-5 (IL-5), eosinophilic granulocyte count, and lactic dehydrogenase (LDH).

The invention relates to a method for rapidly preparing vernonia anthelmintica dealicin from vernonia anthelmintica dealicin, which comprises the following steps: carrying out ultrasonic extraction by using ethanol, enriching by using macroporous resin to obtain a vernonia anthelmintica dealicin extract, and carrying out extraction and pilot plant test preparative liquid chromatography separation to obtain a high-purity vernonia anthelmintica dealicin compound. The results of subsequent researches show that the vernonia anthelmintica dealicin can significantly inhibit the secretion of the chemotactic factor, and the inhibition rate of 1mol / L of vernonia anthelmintica dealicin on the release level of the chemotactic factor CXCL10 reaches 75.83%. The vernonia anthelmintica macrobrachin reduces the recruitment of self-reactive T cells to the skin by blocking a CXCL10-mediated inflammation signal channel, so that melanocytes are protected, and pigment regeneration is promoted. Therefore, the vernonia anthelmintica macrobrachin inhibits the secretion of the chemotactic factor CXCL10 in a targeted manner, can be used as a potential effective monomeric compound in the development of vitiligo medicines for research, and is expected to become a new strategy for treating vitiligo.

The present disclosure generally relates to a viral vector carrying a synthetic cancer antigen and a chemokine. Also provided herein are compositions and uses of the viral vector for delivering, such as tagging, a tumor with the synthetic cancer antigen.

The present invention relates to anti-chemokine-like receptor 1 antibodies and therapeutic uses thereof. The present invention provides anti-CMKLR1 compounds having agonist ability for the interaction between Resolvin E1 and CMKLR1, and their use in the treatment or prevention of diseases, particularly diseases in which inflammation regression is delayed or disrupted.

The application discloses application of DUSP4 in preparation of a marker for predicting the curative effect of immunotherapy of hepatocellular carcinoma and a sensitizing drug, and belongs to the technical field of biological medicine.The application finds that high expression of dual specificity phosphatase 4 (DUSP4) is significantly related to high response rate and long survival period of an immunological checkpoint blocking therapy for a hepatocellular carcinoma patient.DUSP4 promotes CD8+ T cell and NK cell infiltration and remodels an immune microenvironment by inhibiting a TGF-beta signal path, down-regulating an immunosuppressive factor and up-regulating an antigen presenting molecule and a chemotactic factor.The application provides a kit and a method for detecting the expression level of DUSP4 to predict an immunotherapy response, and a combined drug composition comprising a DUSP4 activator or a TGF-beta inhibitor and an immunological checkpoint inhibitor.Experiments prove that up-regulation of the expression of DUSP4 can significantly enhance T cell killing function, and produces a synergistic anti-tumor effect with an anti-PD-1 antibody.The application provides a new strategy for precise stratified treatment and overcoming immunological drug resistance of hepatocellular carcinoma.

The present application relates to a model for predicting the age of a rat, which considers data of immune cells, or data of immune cells, and data of cytokine and / or chemokine levels to predict the age of a rat. The model of the present application significantly improves the accuracy and reliability of age prediction, provides strong support for personalized health management, and helps to promote the development of precision medicine, and ultimately aims to achieve the goal of extending healthy life.

Disclosed are a glycerol derivative that is useful for improving, preventing or treating inflammation-related diseases by inhibiting overexpression of various inflammatory cytokines such as IL-4, IL-6 and so on, or chemokine CXCL8 and reducing migration of HL-60 cell lines, preparation method therefor, and an immunomodulator containing the same as active ingredient. It includes a glycerol derivative represented by Chemical formula 2 or 3 in the specification.

The present invention relates to a peptide for preventing or treating chronic obstructive pulmonary disease (COPD) and a use thereof. Specifically, the peptide prepared according to the present invention reduces the production of chemokines and inflammatory cytokines involved in pulmonary dysfunction in a COPD animal model, decreases the expression of genes causing excessive mucus production and the secretion of airway resistance factors, and exhibits the effect of inhibiting an increase in neutrophils, which are key cells related to COPD pathogenesis. Thus, the peptide can be effectively used as an active ingredient in a composition for preventing or treating COPD.